https://www.fool.com/investing/2024/02/11/these-17-words-from-abbvies-ceo-explain-why-the-st/?source=iedfolrf0000001
Feb 11, 2024 - The drugmaker is handling its biggest obstacle yet relatively well.
0
fool:-8318075730336580254
0
https://www.fool.com/investing/2024/02/06/2-magnificent-dividend-growth-stocks-to-load-up-on/?source=iedfolrf0000001
Feb 06, 2024 - These two dividend-growth stocks are fantastic buys.
0
fool:1497019338593134374
0
https://www.fool.com/investing/2024/02/03/7-dividend-stocks-that-pay-me-more-than-500-per-mo/?source=iedfolrf0000001
Feb 03, 2024 - These stocks pay safe, reliable, and growing dividends.
0
fool:-8143902548400009636
0
https://www.fool.com/earnings/call-transcripts/2024/02/02/abbvie-abbv-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Feb 02, 2024 - ABBV earnings call for the period ending December 31, 2023.
0
fool:5985633829788512551
0
https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-2220511
Feb 02, 2024 - AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
zc:-2017038614076952031
0
https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-3-7-unemployment?cid=CS-ZC-FT-ahead_of_wall_street-2220369
Feb 02, 2024 - 353K new jobs created for January are nearly double the 180K or so analysts were looking for.
zc:2410887625410279442
0
https://www.zacks.com/stock/news/2220349/abbvie-abbv-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2220349
Feb 02, 2024 - The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:-1939447443469848350
0
https://www.fool.com/investing/2024/01/28/2-high-yield-healthcare-stocks-to-buy-with-both-ha/?source=iedfolrf0000001
Jan 28, 2024 - All three of these stocks offer attractive dividend yields, but one looks risky.
0
fool:-41357777271798013
0
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
zc:5586419536017940380
0
https://www.zacks.com/commentary/2210770/q4-earnings-season-scorecard-and-analyst-reports-for-apple-abbvie-toyota?cid=CS-ZC-FT-research_daily-2210770
Jan 16, 2024 - Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on Apple (AAPL), AbbVie (ABBV), Toyota Motor (TM) and others.
zc:134670486518692472
0